Alkermes' LUMRYZ Phase 3 Study for Idiopathic Hypersomnia Meets All Endpoints

summarizeSummary

Alkermes announced positive topline results from its Phase 3 REVITALYZ study, showing LUMRYZ significantly improved excessive daytime sleepiness and disease severity in adults with idiopathic hypersomnia. The company plans to file an sNDA by year-end 2026, though marketing for this indication is restricted until March 2028.

check_boxKey Events

• Positive Phase 3 Results

  LUMRYZ met all primary and key secondary endpoints in the REVITALYZ study for idiopathic hypersomnia, demonstrating statistically significant improvements in excessive daytime sleepiness and disease severity.

• Consistent Safety Profile

  The safety profile of LUMRYZ in the study was consistent with previously observed data, with no new safety signals identified.

• Planned sNDA Submission

  Alkermes intends to file a supplemental New Drug Application (sNDA) with the FDA by the end of 2026 for this new indication.

• Marketing Restriction

  Commercialization of LUMRYZ for idiopathic hypersomnia is restricted until March 1, 2028, even if FDA approval is received earlier, due to a previously disclosed settlement.

auto_awesomeAnalysis

This filing reports successful Phase 3 clinical trial results for LUMRYZ in idiopathic hypersomnia, a rare sleep disorder with limited treatment options. Meeting all primary and key secondary endpoints with a consistent safety profile is a significant positive for Alkermes, expanding the potential market for an already approved drug. While an sNDA filing is planned for late 2026, commercialization for this new indication is restricted until March 2028 due to a prior settlement, delaying potential revenue generation.